- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lucio Gordan Names His Most Exciting Development in Oncology in the Last Year
New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.
New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.
Transcript (slightly modified)
There have been a number of developments in oncology treatment in the last year: which of those do you find the most clinically exciting?
There are several. Obviously, we cannot go in oncology without speaking about immunotherapy, the new biologics. Those drugs are potentially changing the landscape as to how we treat patients with lung cancer, melanoma, and others. So I think this is the most critical component as far as developments. We have had several new drugs approved for multiple myeloma for this year and how to sequence these drugs is a challenge.
Another important point of the clinical track that we discuss for the community of oncology physicians is to make sure that we always support clinical trial enrollment. This is the only way we can move the science forward and get our patients to do better. But, I think immunotherapy is the blockbuster for 2016.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
